Efficacy, Effectiveness, and Implementation of Jaspr Health in Emergency Department- Part B

Summary

This Study will evaluate the implementation of a multi-component suicide prevention technology (Jaspr Health) that facilitates delivery of suicided-related evidence-based practices (EBPs) while replacing wasted waiting time with productive time in the Emergency Departments (EDs). The EBPs satisfy several key performance elements for systems adopting Zero Suicide.

A Complementary Randomized Controlled Trial and Real-World Study for Efficacy, Effectiveness, and Implementation Study Design (CREID) will be used

Conditions

• Suicidal Ideation
• Suicide Attempt
• Self Harm

Interventions

DEVICE

Jaspr App

Jaspr was designed to improve delivery of evidence-based, personalized suicide care in the ED. Jaspr (Dimeff, R44MH108222) is rooted in EBPs, including Collaborative Assessment and Management of Suicide (CAMS) and Dialectical Behavior Therapy (DBT). Briefly, Jaspr provides a patient interface, optimized for a tablet computer provided to the patient, which uses an avatar to administer: (1) the CAMS Suicide Status Form (SSF), an evidence-based suicide risk assessment; (2) crisis stabilization planning (CAMS' version of safety planning) or Stanley-Brown Safety Planning Intervention, depending on site choice; (3) lethal means safety counseling. Further, Jaspr teaches behavioral skills from DBT to manage imminent distress and has a library of over 40 racially and culturally diverse, inspirational videos of people with lived experience. Finally, Jaspr@home provides access to these resources after the visit during the high-risk transition to outpatient care.

Sponsors & Collaborators

• Ohio State University

  collaborator OTHER

• Evidence-Based Practice Institute, Seattle, WA

  collaborator INDUSTRY

• National Institute of Mental Health (NIMH)

  collaborator NIH

• Worcester Polytechnic Institute

  collaborator OTHER

• University of Colorado, Denver

  collaborator OTHER

• University of Massachusetts, Worcester

  lead OTHER

Principal Investigators

• Edwin D Boudreaux, PhD · UMass Chan Medical School

Study Design

Allocation

NON_RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Model

SEQUENTIAL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-11-07

Primary Completion

2027-06-01

Completion

2027-06-01

FDA Device

Yes

Countries

• United States

Study Locations